Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exquisite response to imatinib mesylate in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome: a 12-year experience of the Polish Hypereosinophilic Syndrome Study Group.

Polish archives of internal medicine - 27 Mar 2020

Helbig Grzegorz, Lewandowski Krzysztof, Świderska Alina, Rodzaj Marek, Seferyńska Ilona, Gajkowska-Kulik Justyna

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hypereosinophilic Syndrome
Share to Imatinib Mesylate
Share to mRNA Cleavage and Polyadenylation Factors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oncogene Proteins, Fusion

Share to Poland

Share to Protein Kinase Inhibitors

Share to Receptor, Platelet-Derived Growth Factor alpha

Share to Treatment Outcome

Source

Identifiers

PMID: 32125294
DOI: 10.20452/pamw.15224

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exquisite response to imatinib mesylate in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome: a 12-year experience of the Polish Hypereosinophilic Syndrome Study Group.PMID 32125294Read ↗

Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.Semantic proximity Read ↗

Imatinib for the treatment of hypereosinophilic syndromes.Semantic proximity Read ↗

Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome.Semantic proximity Read ↗

The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and managementSemantic proximity Read ↗

Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.Semantic proximity Read ↗

[FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutant of PDGFRA gene: a case report and literature review].Semantic proximity Read ↗

Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder.Semantic proximity Read ↗

Idiopathic Hypereosinophilic Syndrome in ChildrenSemantic proximity Read ↗

Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcriptSemantic proximity Read ↗

Phase II trial of imatinib mesylate in patients with PDGFRA/B-negative hypereosinophilic syndrome.Semantic proximity Read ↗

The FIP1L1-PDGFR?? kinase in hypereosinophilic syndrome and chronic eosinophilic leukemiaSemantic proximity Read ↗

Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophiliaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.